{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T04:24:43Z","timestamp":1774326283204,"version":"3.50.1"},"reference-count":48,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T00:00:00Z","timestamp":1656374400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014114","name":"GW Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014114","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Brain and Behavior"],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The onset of severe, drug\u2010resistant seizures in early childhood is characteristic of the rare epileptic disorders Lennox\u2010Gastaut syndrome (LGS), Dravet syndrome (DS), and CDKL5 deficiency disorder (CDD) and is frequently observed in the rare genetic conditions tuberous sclerosis complex (TSC) and Rett syndrome (RTT). High\u2010quality treatment guidelines are needed for optimal management of these conditions. This review aimed to assess content, availability, and development of treatment guidelines for these disorders in the Nordics region (Denmark, Finland, Iceland, Norway, and Sweden).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A targeted literature review (TLR) was therefore conducted in November\/December 2020 by manually searching online rare disease and guideline databases in addition to relevant health technology assessment and regulatory agency websites to identify pharmacological treatment guidelines for DS, LGS, TSC, RTT, and CDD. Search terms for each disorder were translated to identify country\u2010specific guidelines. Treatment recommendations, geographical focus, and guideline development methodology was extracted into a predetermined extraction grid.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Most of the 24 eligible guidelines identified (16\/24; 66%) were specific to particular countries; Sweden was the most represented (7\/24 [29%] guidelines), while no guidelines were identified for Iceland. Guideline development methodologies were heterogeneous, including systematic literature reviews\/TLRs and expert consultation; several methodologies did not report details on the evidence sources used (7\/24 [29%] guidelines). Treatment recommendation availability was variable across disorders, ranging from 126 treatment recommendations (LGS) to none (RTT, CDD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Comprehensive, consensus\u2010based treatment guidance developed via international collaboration within the Nordics region is necessary to optimize patient care in these five rare epileptic conditions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/brb3.2622","type":"journal-article","created":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T01:59:22Z","timestamp":1656467962000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Nordic treatment guidelines for rare epileptic conditions: A literature review"],"prefix":"10.1002","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0944-9608","authenticated-orcid":false,"given":"Kishan","family":"Vyas","sequence":"first","affiliation":[{"name":"GW Pharmaceuticals (A Jazz Pharmaceuticals company) London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah","family":"Luedke","sequence":"additional","affiliation":[{"name":"Costello Medical Cambridge UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9040-1902","authenticated-orcid":false,"given":"Benjamin","family":"Ruban\u2010Fell","sequence":"additional","affiliation":[{"name":"Costello Medical Cambridge UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,6,28]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2016.08.725"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i1152"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/pnp.422"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528\u20101167.2011.03177.x"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpn.2018.05.006"},{"key":"e_1_2_9_7_1","unstructured":"Det Nationale Institut for Kommuners og Regioners Analyse og Forskning. (2015).Nordic networks on rare diseases \u2013 Ideas for future cross functional networks."},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2019.01.010"},{"key":"e_1_2_9_9_1","unstructured":"European Medicines Agency. (2018a).Assessment report: medicinal products containing substances related to valproate."},{"key":"e_1_2_9_10_1","unstructured":"European Medicines Agency. (2018b).Valproate and related substances."},{"key":"e_1_2_9_11_1","unstructured":"European Medicines Agency. (2019).EU\/3\/14\/1339: Cannabidiol."},{"key":"e_1_2_9_12_1","unstructured":"European Medicines Agency. (2020).EU\/3\/13\/1219: Fenfluramine hydrochloride."},{"key":"e_1_2_9_13_1","unstructured":"European Medicines Agency. (2021).EU\/3\/17\/1959: Cannabidiol."},{"key":"e_1_2_9_14_1","unstructured":"Food and Drug Administration. (2018).Drug approval package: Diacomit (stiripentol).https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/206709Orig1s000 207223Orig1s000TOC.cfm"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2016.10.014"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39490.551019.BE"},{"key":"e_1_2_9_17_1","first-page":"D003277","article-title":"Treatment of Lennox\u2010Gastaut syndrome","author":"Hancock E. C. H.","year":"2003","journal-title":"Cochrane Database of Systematic Reviews (Online)"},{"key":"e_1_2_9_18_1","unstructured":"Helsebiblioteket. (2016).Epilepsi.https:\/\/www.helsebiblioteket.no\/pediatriveiledere?key=144642&menuitemkeylev1=5962&menuitemkeylev2=5973"},{"key":"e_1_2_9_19_1","unstructured":"Hikmat O.. (2015).Retningslinjer for behandling av barne epilepsi.https:\/\/kvalitet.helse\u2010bergen.no\/docs\/pub\/dok29389.pdf"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/501981"},{"key":"e_1_2_9_21_1","unstructured":"Kaur S. &Christodoulou J.(2019).MECP2 disorders. GeneReviews.https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1497\/"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.2196\/resprot.6902"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/MOP.0b013e32834c9251"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0b013e31823d07d1"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.16546"},{"key":"e_1_2_9_26_1","unstructured":"Mets\u00e4honkala L. et\u00a0al. (2020).Epilepsiat ja kuumekouristukset (lapset ja nuoret).https:\/\/www.kaypahoito.fi\/hoi50059#readmore"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.4137\/JCNSD.S8315"},{"key":"e_1_2_9_28_1","unstructured":"Mol Debes Nea. (2014).Neuropaediatri \u2013 en pixibog.https:\/\/docplayer.dk\/9690321\u2010Neuropaediatri\u2010en\u2010pixibog\u2010tourettes\u2010syndrom\u2010epilepsi\u2010hovedpine\u2010mental\u2010retardering\u2010cerebral\u2010parese\u2010se\u2010vip\u2010for\u2010detaljerede\u2010vejledninger.html"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/epi4.12286"},{"key":"e_1_2_9_30_1","unstructured":"Nakken Kea. (2016).Kunnskapsbasert retningslinje om epilepsi.https:\/\/www.epilepsibehandling.no\/index.php?action=showchapter&chapter=7S7KCFB3"},{"key":"e_1_2_9_31_1","unstructured":"Nascimento F. A. &Andrade D. M.(2017).Dravet Syndrome: Management and prognosis."},{"key":"e_1_2_9_32_1","unstructured":"National Institute for Health and Care Excellence. (2017).Stiripentol.https:\/\/bnfc.nice.org.uk\/drug\/stiripentol.html"},{"key":"e_1_2_9_33_1","unstructured":"National Organization for Rare Disorders. (2020a).CDKL5 deficiency disorder."},{"key":"e_1_2_9_34_1","unstructured":"National Organization for Rare Disorders. (2015). Rett syndrome."},{"key":"e_1_2_9_35_1","unstructured":"National Organization for Rare Disorders. (2019). Tuberous sclerosis."},{"key":"e_1_2_9_36_1","unstructured":"National Organization for Rare Disorders. (2020b).Lennox\u2010Gastaut syndrome."},{"key":"e_1_2_9_37_1","unstructured":"National Organization for Rare Disorders. (2018).Dravet syndrome."},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.12941"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528\u20101167.2010.02597.x"},{"key":"e_1_2_9_40_1","unstructured":"Nordic Innovation. (2015).Ecosystem for Nordic clinical practice guidelines."},{"key":"e_1_2_9_41_1","unstructured":"Northrup H. Koenig M. Pearson D. &Au K. S.(2018).Tuberous sclerosis complex. GeneReviews.http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1220\/"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2019.02.015"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1080\/21675511.2015.1058463"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0170365"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0170365"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2020.1801423"},{"key":"e_1_2_9_47_1","unstructured":"UpToDate. (2017).Dravet syndrome: Management and prognosis."},{"key":"e_1_2_9_48_1","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1684\/epd.2007.0144","article-title":"Treatment of pediatric epilepsy: European expert opinion, 2007","volume":"9","author":"Wheless J. C. D.","year":"2007","journal-title":"Epileptic Disorders"},{"key":"e_1_2_9_49_1","unstructured":"World Health Organisation. (2014).WHO handbook for guideline development."}],"container-title":["Brain and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/brb3.2622","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/brb3.2622","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/brb3.2622","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T20:34:59Z","timestamp":1727469299000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/brb3.2622"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,28]]},"references-count":48,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["10.1002\/brb3.2622"],"URL":"https:\/\/doi.org\/10.1002\/brb3.2622","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1002\/BRB3.2622\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/BRB3.2622\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/BRB3.2622\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/BRB3.2622\/v1\/review1","asserted-by":"object"}]},"ISSN":["2162-3279","2162-3279"],"issn-type":[{"value":"2162-3279","type":"print"},{"value":"2162-3279","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,28]]},"assertion":[{"value":"2021-12-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e2622"}}